Evidence mapPaperPMID 38934370Full record

SynthesisJournal of gastroenterology and hepatology2024

Prevalence of small intestinal bacterial overgrowth in intestinal failure syndrome: A systematic review and meta-analysis.

Ayesha Shah, Thomas Fairlie, Mark Morrison, Neal Martin, Karin Hammer, Johann Hammer, Natasha Koloski, Ali Rezaie, Mark Pimentel, Purna Kashyap and 2 more

Abstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in Journal of gastroenterology and hepatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ayesha ShahFaculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.
Thomas FairlieFaculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.
Mark MorrisonFaculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.
Neal MartinFaculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.
Karin HammerSt. Anna Kinderspital, Medical University of Vienna, Vienna, Austria.
Johann HammerDepartment of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
Natasha KoloskiFaculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.
Ali RezaieKarsh Division of Gastroenterology and Hepatology, Department of Medicine, Medically Associated Science and Technology (MAST) Program, Cedars-Sinai, Los Angeles, California, USA.
Mark PimentelKarsh Division of Gastroenterology and Hepatology, Department of Medicine, Medically Associated Science and Technology (MAST) Program, Cedars-Sinai, Los Angeles, California, USA.
Purna KashyapDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Michael P JonesSchool of Psychological Sciences, Macquarie University, Sydney, New South Wales, Australia.
Gerald HoltmannFaculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.ORCID https://orcid.org/0000-0002-0206-2358

Funding

MECHANISMS OF VISCERAL PAIN DRIVEN BY SMALL INTESTINAL MICROBIOTAR01DK138818 · MAYO CLINIC ROCHESTER · 2025 to 2025
$803k
Mechanisms of alteration of gastrointestinal physiology by gut microbesR01DK114007 · MAYO CLINIC ROCHESTER · 2025 to 2025
$584k
Centre for Research Excellence APP170993National Health and Medical Research Council APP2004495NIDDK NIH HHS R01 DK114007NIDDK NIH HHS R01 DK138818
6 · The paper itself

Abstract

BACKGROUND AND

aimPatients with intestinal failure (IF) have abnormal intestinal anatomy, secretion, and dysmotility, which impairs intestinal homeostatic mechanisms and may lead to small intestinal bacterial overgrowth (SIBO). We conducted a systematic review and meta-analysis to determine the prevalence of SIBO in patients with IF and to identify risk factors for SIBO.

methodsMEDLINE (PubMed) and Embase electronic databases were searched from inception to December 2023 for studies that reported the prevalence of SIBO in IF. The prevalence rates, odds ratio (OR), and 95% confidence intervals of SIBO in IF and the risk factors for SIBO in IF were calculated using random effects model.

resultsFinal dataset included nine studies reporting on 407 patients with IF. The prevalence of SIBO in IF was 57.5% (95% CI 44.6-69.4), with substantial heterogeneity in this analysis (I

conclusionsThis systematic review and meta-analysis suggests that there is an increased risk of SIBO in patients with IF and that PN, and potentially, the use of PPI/acid-suppressing agents is risk factors for SIBO development in patients with IF. However, the quality of evidence is low and can be attributed to lack of case-control studies and clinical heterogeneity seen in the studies.

Indexed as

Intestine, SmallBlind Loop SyndromeGastrointestinal MicrobiomeHumansIntestinal DiseasesParenteral NutritionPrevalenceRisk Factorsbacterial overgrowthbreath testsintestinal failureprevalenceshort gut syndromeSIBO

Identifiers

PMID38934370
PMCPMC11618250

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.